Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
28.7 USD +3.09% Intraday chart for Arrowhead Pharmaceuticals, Inc. +1.92% -6.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran CI
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy CI
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024. CI
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024. CI
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024 CI
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating MT
Sector Update: Health Care Stocks Firmer Late Afternoon MT
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 06, 2024
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing MT
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024 CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing MT
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
Arrowhead Pharmaceuticals Shares Rise as $450 Million Underwritten Share Offering Priced MT
Arrowhead Pharmaceuticals Prices $450 Million Underwritten Share Offering MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $342,480, According to a Recent SEC Filing MT
North American Morning Briefing : China Outlook -2- DJ
BofA Securities Initiates Arrowhead Pharmaceuticals at Buy Rating With $29 Price Target MT
B. Riley Lowers Arrowhead Pharmaceuticals' Price Target to $50 From $60, Notes Higher Cash Burn; Keeps Buy Rating MT
Chart Arrowhead Pharmaceuticals, Inc.
More charts
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
28.7 USD
Average target price
55.15 USD
Spread / Average Target
+92.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq
  4. News Arrowhead Pharmaceuticals, Inc.
  5. Arrowhead Pharmaceuticals : Significant Insider Selling in Shares of Arrowhead Pharmaceuticals (ARWR) Continues